Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

被引：6

作者：

Jacques, Sarah K. ^{[1
,2
]}

McKeown, Janet ^{[3
]}

Grover, Piyush ^{[3
]}

Johson, Douglas B. ^{[4
]}

Zaremba, Anne ^{[5
]}

Dimitriou, Florentia ^{[6
,7
]}

Weiser, Roi ^{[24
]}

Farid, Mohamad ^{[8
]}

Namikawa, Kenjiro ^{[9
]}

Sullivan, Ryan J. ^{[10
]}

Rutkowski, Piotr ^{[11
]}

Lebbe, Celeste ^{[12
]}

Hamid, Omid ^{[13
]}

Zager, Jonathan S. ^{[14
]}

Michielin, Olivier ^{[15
]}

Neyns, Bart ^{[16
]}

Nakamura, Yasuhiro ^{[17
]}

Robert, Caroline ^{[18
,19
]}

Mehnert, Janice ^{[25
]}

Ascierto, Paolo A. ^{[26
]}

Bhave, Prachi ^{[23
]}

Park, Benjamin ^{[4
]}

Zimmer, Lisa ^{[5
]}

Mangana, Joanna ^{[6
,11
]}

Mooradian, Megan ^{[10
]}

Placzke, Joanna ^{[7
]}

Allayous, Clare ^{[12
]}

Oliva, Isabella C. Glitza ^{[24
]}

Mehmi, Inderjit ^{[13
]}

Depalo, Danielle ^{[14
]}

Wicky, Alexandre ^{[15
]}

Schwarze, Julia K. ^{[16
]}

Roy, Severine ^{[18
]}

Boatwright, Christina ^{[25
]}

Vanella, Vito ^{[26
]}

Long, Georgina, V ^{[3
,20
,21
]}

Menzies, Alexander M. ^{[3
,20
,21
,22
]}

Lo, Serigne N. ^{[3
,20
]}

Carlino, Matteo S. ^{[1
,2
,3
,27
]}

机构：

[1] Westmead Hosp, Dept Med Oncol, Sydney, Australia

[2] Blacktown Hosp, Dept Med Oncol, Sydney, Australia

[3] Univ Sydney, Melanoma Inst Australia, Sydney, Australia

[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[5] Univ Hosp Essen, Dept Dermatol Venereol & Allergol, Essen, Germany

[6] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland

[7] Univ Zurich, Fac Med, Zurich, Switzerland

[8] Natl Canc Ctr, Singapore, Singapore

[9] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[10] Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA

[11] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[12] Univ Paris Cite, St Louis Hosp, Canc Inst AP HP Nord Paris Cite, INSERM U976,AP HP Dermatooncol, Paris, France

[13] Angeles Clin, Los Angeles, CA USA

[14] Moffit Canc Ctr, Dept Cutaneous Oncol, Tampa, FL USA

[15] Lausanne Univ Hosp, Dept Oncol, Lausanne, Switzerland

[16] Univ Ziekenhuis Brussel, Brussels, Belgium

[17] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Skin Oncol Dermatol, Saitama, Japan

[18] Inst Gustave Roussy, Villejuif, France

[19] Paris Saclay Univ, Villejuif, France

[20] Univ Sydney, Fac Med & Hlth, Sydney, Australia

[21] Royal North Shore Hosp, Sydney, Australia

[22] Mater Hosp, Sydney, Australia

[23] Univ Melbourne, Sir Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Vic, Australia

[24] MD Anderson Canc Ctr, Houston, TX USA

[25] NYU Langone, New York, NY USA

[26] Ist Nazl Tumori IRCCS Fdn Pascale, Naples, Italy

[27] Westmead Hosp, Crown Princess Mary Canc Ctr, 166-174 Hawkesbury Rd, Westmead, NSW 2145, Australia

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 199卷

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

Acral melanoma; Mucosal melanoma; Adjuvant; Immunotherapy; Anti-PD1; IMMUNE CHECKPOINT INHIBITORS;

D O I：

10.1016/j.ejca.2024.113563

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Importance: Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in non-acral cutaneous melanoma. Objective: To determine the efficacy of adjuvant PD1 in resected AM or MM. Design: An international, retrospective cohort study Setting: Data up to November 2021 collected from 20 centres across 10 countries. Participants: One hundred and ninety four patients with resected stage III or IV1 AM or MM who received adjuvant PD1 were included and compared to matched patients from the Melanoma Institute Australia (MIA) database using a propensity score matching analysis. Main outcomes and measures: Recurrence -free survival (RFS), distant metastasis -free survival (DMFS) and overall survival (OS) were investigated. Results: Forty five of 139 (32%) AM and 9 of 55 (16%) MM patients completed adjuvant therapy. The main reason for early treatment cessation in both groups was disease recurrence: 51 (37%) and 30 (55%) in the AM and MM groups, respectively. In the AM group adjuvant PD1 was associated with a longer RFS [HR -0.69 (0.52-0.92, p = 0.0127)], DMFS [HR0.58 (0.38-0.89, p = 0.0134)] and OS [HR of 0.59 (0.38-0.92, p -value 0.0196)] when compared to the historical cohort. In the MM group there was no statistical difference in RFS [HR1.36 (0.69-2.68,p -value 0.3799], DMFS or OS. Conclusion and relevance: After adjuvant PD1, both AM and MM have a high risk of recurrence. Our data suggests a benefit to using adjuvant PD1 therapy in resected AM but not in resected MM. Additional studies to investigate the efficacy of adjuvant PD1 for MM are needed.

引用

页数：8

共 50 条

[21] Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
Woodford, Rachel
McKeown, Janet
Hoeijmakers, Lotte L.
Mangana, Johanna
Dimitriou, Florentia
Allayous, Clara
Zaman, Farzana
Aya, Francisco
Marsiglio, John
Goodman, Rachel
Rayson, Victoria
Placzke, Joanna
Kessels, Jolien
Ramalyte, Egle
Haque, Waqas
Wilson, Isabella
Trojaniello, Claudia
Benannoune, Naima
Roberts-Thomson, Rachel
Robert, Caroline
Blank, Christian U.
Dummer, Reinhard
Lebbe, Celeste
Haydon, Andrew
Arance, Ana
Hu-Lieskovan, Siwen
Johnson, Douglas B.
Mcarthur, Grant A.
Rutkowski, Piotr
Neyns, Bart
Sullivan, Ryan J.
Weber, Jeffrey
Carlino, Matteo S.
Ascierto, Paolo A.
Lo, Serigne
Long, Georgina, V
Menzies, Alexander M.
EUROPEAN JOURNAL OF CANCER, 2024, 212
[22] Anti-PD-1 Therapy in Melanoma
Moreno, Blanca Hornet
Parisi, Giulia
Robert, Lidia
Ribas, Anton
SEMINARS IN ONCOLOGY, 2015, 42 (03) : 466 - 473
[23] Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma
Yunteng Wu
Dongliang Wei
Guoxin Ren
Wei Guo
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2293 - 2300
[24] Toripalimab (anti-PD-1) plus recombinant human endostatin as adjuvant therapy in patients with resected stage III melanoma: Interim analysis of an open-label phase II trial.
Hu, Xianglin
Xu, Yu
Sun, Yang-bai
Yang, Ling-ge
Zheng, Bi-qiang
Sun, Zheng-Wang
Chen, Yong
Yan, Wangjun
Wang, Chun-Meng
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[25] Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma
Wu, Yunteng
Wei, Dongliang
Ren, Guoxin
Guo, Wei
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2293 - 2300
[26] Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Weber, J.
Mandala, M.
Del Vecchio, M.
Gogas, H. J.
Arance, A. M.
Cowey, C. L.
Dalle, S.
Schenker, M.
Chiarion-Sileni, V.
Marquez-Rodas, I.
Grob, J-J.
Butler, M. O.
Middleton, M. R.
Maio, M.
Atkinson, V.
Queirolo, P.
Gonzalez, R.
Kudchadkar, R. R.
Smylie, M.
Meyer, N.
Mortier, L.
Atkins, M. B.
Long, G. V.
Bhatia, S.
Lebbe, C.
Rutkowski, P.
Yokota, K.
Yamazaki, N.
Kim, T. M.
de Pril, V.
Sabater, J.
Qureshi, A.
Larkin, J.
Ascierto, P. A.
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1824 - 1835
[27] Management of resected stage III/IV melanoma with adjuvant immunotherapy.
Johnson, Rebecca
Atkinson, Victoria
Bhave, Prachi
Weppler, Alison Margaret
Peters, Geoffrey David
Abed, Afaf
Lyle, Megan
Khattak, Muhammad Adnan
Haydon, Andrew Mark
Carlino, Matteo S.
Sandhu, Shahneen Kaur
Long, Georgina V.
Menzies, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[28] Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
Joseph, Richard W.
Cappel, Mark
Goedjen, Brent
Gordon, Matthew
Kirsch, Brandon
Gilstrap, Cheryl
Bagaria, Sanjay
Jambusaria-Pahlajani, Anokhi
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (01) : 18 - 22
[29] Clinical Outcomes of Melanoma Brain Metastases Treated With Stereotactic Radiation and Anti-PD-1 Therapy
Ahmed, K. A.
Stallworth, D. G.
Johnstone, P. A. S.
Harrison, L. B.
Etame, A. B.
Weber, J. S.
Gibney, G. T.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S57 - S57
[30] Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy
Ahmed, K. A.
Stallworth, D. G.
Kim, Y.
Johnstone, P. A. S.
Harrison, L. B.
Caudell, J. J.
Yu, H. H. M.
Etame, A. B.
Weber, J. S.
Gibney, G. T.
ANNALS OF ONCOLOGY, 2016, 27 (03) : 434 - 441

← 1 2 3 4 5 →